Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

BURLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced the appointments of Christopher Thompson, M.D. and Ian Sheffield to its Board of Directors. These appointments build on Fractyl’s recent momentum as it advances Revita^® through late-stage development and prepares for its first-in-human clinical study with Rejuva^®.

Read more at globenewswire.com